Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Impact of Allograft T-Cell (CD3) Dose on Outcomes When CD34 Cell Dose Is Capped: Analysis of 811 Consecutive Allogeneic PBSC Transplants from a Single Center

Asad Bashey, Xu Zhang, Lawrence Morris, Kent Holland, Lizamarie Bachier-Rodriguez, Melhem M. Solh, Scott R. Solomon

Blood (2023) 142 (Supplement 1): 2182.

https://doi.org/10.1182/blood-2023-180383

Published: 2023

Journal Articles

Intrathecal Chemotherapy As Treatment for Chimeric Antigen Receptor T Cell (CAR T) Therapy Associated Neurotoxicity

Melhem M. Solh, Asad Bashey, Lawrence Morris, Lizamarie Bachier-Rodriguez, H Kent Holland, Xu Zhang, Katelin C Jackson, Scott R. Solomon

Blood (2023) 142 (Supplement 1): 2138.

https://doi.org/10.1182/blood-2023-186585

Published: 2023

Journal Articles

Impact of an HLA-DPB1 Non-Permissive Mismatch By the Revised T Cell Epitope (TCE)-Core Algorithm on Survival Following Haploidentical Donor Transplantation (HIDT) with Post-Transplant Cyclophosphamide (PTCy)

Scott R. Solomon, Michael T Aubrey, Lizamarie Bachier-Rodriguez, Melhem M. Solh, Katelin C Jackson, Xu Zhang, Christina Roark, H. Kent Holland, Lawrence Morris, Asad Bashey

Blood (2023) 142 (Supplement 1): 2240.

https://doi.org/10.1182/blood-2023-182499

Published: 2023

Journal Articles

Compared to Venetoclax Plus Hypomethylating Agents, High Dose Cytarabine Based Intensive Chemotherapy Induction for Newly Diagnosed Acute Myeloid Leukemia (AML) Leads to a Faster Remission Resulting in Better Survival

Melhem M. Solh, Scott R. Solomon, Lawrence Morris, H Kent Holland, Lizamarie Bachier-Rodriguez, Xu Zhang, Katelin C Jackson, Asad Bashey

Blood (2023) 142 (Supplement 1): 2896.

https://doi.org/10.1182/blood-2023-186117

Published: 2023

Journal Articles

Impact of HLA-DQ Heterodimer Group (G1/G2) Mismatch on Relapse and Survival Following Haploidentical Donor Transplantation

Scott R. Solomon, Michael T Aubrey, Xu Zhang, Lizamarie Bachier-Rodriguez, Lawrence Morris, H. Kent Holland, Christina Roark, Katelin C Jackson, Asad Bashey, Melhem M. Solh

Blood (2023) 142 (Supplement 1): 4984.

https://doi.org/10.1182/blood-2023-182503

Published: 2023

Journal Articles

KB-Lanra 1001: A Phase 1b/2 Study of Safety, PK, PD, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib in Combination with the FLT3 Inhibitor Gilteritinib in FLT3-Mutated R/R AML

Monteserrat Arnan, Anand Ashwin Patel, Jordi Esteve, Lawrence Morris, Gary J. Schiller, Ronan T. Swords, Juan M. Alonso-Dominguez, Laura C. Michaelis, Naval Daver, Luis A. Carvajal, Gordon Bray, Elizabeth Olek, Richard E. Cutler, Jorge F. DiMartino, Eytan M. Stein

Blood (2023) 142 (Supplement 1): 5973.

https://doi.org/10.1182/blood-2023-178804

Published: 2023

Journal Articles

Immunosuppression Free at One-Year Post Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)

Melhem M. Solh, Scott R. Solomon, Lawrence Morris, Lizamarie Bachier-Rodriguez, H Kent Holland, Xu Zhang, Katelin C Jackson, Asad Bashey

Blood (2023) 142 (Supplement 1): 4945.

https://doi.org/10.1182/blood-2023-187505

Published: 2023

Journal Articles

The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

Blood (2023) 142 (Supplement 1): 109.

https://doi.org/10.1182/blood-2023-173855

Published: 2023

Journal Articles

Comparison of Condensed to Standard Schedule of High Dose Cytarabine Consolidation for Acute Myeloid Leukemia in First Complete Remission

Melhem M. Solh, Kristen Kilby, Jimena Baron, Xu Zhang, Asad Bashey, H Kent Holland, Lizamarie Bachier-Rodriguez, Lawrence Morris, Scott R. Solomon

Blood (2023) 142 (Supplement 1): 5939.

https://doi.org/10.1182/blood-2023-186662

Published: 2023

Journal Articles

Post-Transplant Maintenance in AML and MDS Patients Undergoing Non-Myeloablative Peripheral Blood Stem Cell Transplant with Post-Transplant Cyclophosphamide

Lan Lei, Asad Bashey, Scott R. Solomon, Lawrence Morris, H Kent Holland, Melhem M. Solh, Katelin C Jackson, Xu Zhang, Lizamarie Bachier Rodriguez

Blood (2023) 142 (Supplement 1): 6968.

https://doi.org/10.1182/blood-2023-190663

Published: 2023

Journal Articles

Effect of HLA-DPB1 Mismatch on Incidence and Severity of Chronic Graft-Versus-Host Disease Following Haploidentical Transplantation

Scott R. Solomon, Melhem M. Solh, Asad Bashey, Lizamarie Bachier-Rodriguez, Xu Zhang, Lawrence Morris, H. Kent Holland

Blood (2023) 142 (Supplement 1): 2193.

https://doi.org/10.1182/blood-2023-182495

Published: 2023

Journal Articles

Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia

Jonathan Allen Webster, MD, Raoul Tibes, MD PhD, Amanda Blackford, ScM, Lawrence Morris, MD, Mrinal M Patnaik, MBBS, Lihua Wang, PhD, Melanie Rebechi, BS, Jacqueline Greer, RN, Mark R Litzow, MD, Larry Karnitz, PhD, Gary L. Rosner, Austin Doyle, MD, Scott H. Kaufmann, MD PhD, Judith E Karp, MD, B. Douglas Smith, MD

Blood (2015) 126 (23): 2563.

https://doi.org/10.1182/blood.V126.23.2563.2563

Published: 2015

Journal Articles

Total Outpatient Care for Myeloablative Unrelated Donor Hematopoietic Cell Transplantation: A Safe and Effective Alternative to Standard In-Patient Care

Connie A. Sizemore, Pharm.D., Karen Manion, RN, Lawrence Morris, MD, Asad Bashey, MD, PhD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2010) 116 (21): 3525.

https://doi.org/10.1182/blood.V116.21.3525.3525

Published: 2010

Journal Articles

The Impact of a Pre-Existing Psychiatric Diagnoses on a Newly Diagnosed Acute Leukemia Patient's Emotional Functioning During Induction Chemotherapy as Measured by the Brief Symptom Inventory-18 (BSI-18).

Dawn Speckhart, Ph.D., Scott R. Solomon, MD, Asad Bashey, MD, PhD, Lawrence Morris JR, MD, Tina Berry, MS, H. Kent Holland, MD

Blood (2010) 116 (21): 1505.

https://doi.org/10.1182/blood.V116.21.1505.1505

Published: 2010

Journal Articles

Improved Survival using Dual Monoclonal Antibody Therapy with Aggressive Anti-Microbial Prophylaxis In Steroid-Refractory Acute Graft-Versus-Host Disease

Melissa Sanacore, PharmD, Karen Manion, RN, Pauline Smith, RN, Xu Zhang, PhD, H. Kent Holland, MD, Lawrence Morris, MD, Scott R. Solomon, MD, Asad Bashey, MD, PhD

Blood (2010) 116 (21): 1262.

https://doi.org/10.1182/blood.V116.21.1262.1262

Published: 2010

Journal Articles

Minimizing Therapy for Patients with Acute Promyelocytic Leukemia: Efficacy of Single Cycle of Arsenic-Based Consolidation Therapy.

Steven D. Gore, MD, Lawrence Morris, MD, Ivana Gojo, MD, Marcel P. Devetten, MD, Katarzyna Jamieson, MD, Mikkael A. Sekeres, MD, MS, Robert J. Arceci, MD, PhD, Robert L. Redner, MD, Tianna Dauses, BSN, Esther L Schachter-Tokarz, Ibitayo Owoeye, MD, Robert E. Gallagher, MD

Blood (2008) 112 (11): 1932.

https://doi.org/10.1182/blood.V112.11.1932.1932

Published: 2008

Journal Articles

Active Oral Regimen for Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML): Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults ≥Age 70 Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

Judith E. Karp, MD, Eric J. Feldman, MD, Lawrence Morris, MD, Jacqueline Greer, RN, Valerie Ironside, RN, B. Douglas Smith, MD, Ellen Ritchie, MD, Steven D. Gore, MD, Mark J. Levis, MD,PhD, Scott H. Kaufmann, MD,PhD, Sami Malek, MD, John J. Wright, MD,PhD

Blood (2006) 108 (11): 426.

https://doi.org/10.1182/blood.V108.11.426.426

Published: 2006

Journal Articles

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

Jeffrey E. Lancet, Ivana Gojo, Jason Gotlib, Eric J. Feldman, Jacqueline Greer, Jane L. Liesveld, Laura M. Bruzek, Lawrence Morris, Youn Park, Alex A. Adjei, Scott H. Kaufmann, Elizabeth Garrett-Mayer, Peter L. Greenberg, John J. Wright, Judith E. Karp

Blood (2006) 109 (4): 1387–1394.

https://doi.org/10.1182/blood-2006-04-014357

Published: 2006

Journal Articles

Tipifarnib (Zarnestra, R115777) as Maintenance Therapy for Adults in Complete Remission (CR) Following Induction and Consolidation Therapies for Poor-Risk Acute Myelogenous Leukemia (AML): A Phase II Trial.

Judith E. Karp, MD, Ivana Gojo, MD, Jacqueline Greer, R.N., B. Douglas Smith, MD, Maureen Klein, R.N., Jeffery E. Lancet, MD, Steven D. Gore, MD, Lawrence Morris, MD, Alain Thibault, MD, Mary Ellen Rybak, MD, John J. Wright, MD, PhD

Blood (2005) 106 (11): 2783.

https://doi.org/10.1182/blood.V106.11.2783.2783

Published: 2005

Journal Articles

Tipifarnib (ZARNESTRA TM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.

Jeffrey E. Lancet, MD, Jason Gotlib, MD, Ivana Gojo, MD, Eric J. Feldman, MD, Lawrence Morris, MD, Alain Thibault, MD, Jane L. Liesveld, MD, Jacqueline Greer, RN, Kathleen Dugan, RN, Mitch Raponi, PhD, John J. Wright, MD, PhD, Peter L. Greenberg, MD, Judith E. Karp, MD

Blood (2004) 104 (11): 874.

https://doi.org/10.1182/blood.V104.11.874.874

Published: 2004

NARROW

Impact of Allograft T-Cell (CD3) Dose on Outcomes When CD34 Cell Dose Is Capped: Analysis of 811 Consecutive Allogeneic PBSC Transplants from a Single Center

Intrathecal Chemotherapy As Treatment for Chimeric Antigen Receptor T Cell (CAR T) Therapy Associated Neurotoxicity

Impact of an HLA-DPB1 Non-Permissive Mismatch By the Revised T Cell Epitope (TCE)-Core Algorithm on Survival Following Haploidentical Donor Transplantation (HIDT) with Post-Transplant Cyclophosphamide (PTCy)

Compared to Venetoclax Plus Hypomethylating Agents, High Dose Cytarabine Based Intensive Chemotherapy Induction for Newly Diagnosed Acute Myeloid Leukemia (AML) Leads to a Faster Remission Resulting in Better Survival

Impact of HLA-DQ Heterodimer Group (G1/G2) Mismatch on Relapse and Survival Following Haploidentical Donor Transplantation

KB-Lanra 1001: A Phase 1b/2 Study of Safety, PK, PD, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib in Combination with the FLT3 Inhibitor Gilteritinib in FLT3-Mutated R/R AML

Immunosuppression Free at One-Year Post Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)

The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT-CTN Study 1704

Comparison of Condensed to Standard Schedule of High Dose Cytarabine Consolidation for Acute Myeloid Leukemia in First Complete Remission

Post-Transplant Maintenance in AML and MDS Patients Undergoing Non-Myeloablative Peripheral Blood Stem Cell Transplant with Post-Transplant Cyclophosphamide

Effect of HLA-DPB1 Mismatch on Incidence and Severity of Chronic Graft-Versus-Host Disease Following Haploidentical Transplantation

Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia

Total Outpatient Care for Myeloablative Unrelated Donor Hematopoietic Cell Transplantation: A Safe and Effective Alternative to Standard In-Patient Care

The Impact of a Pre-Existing Psychiatric Diagnoses on a Newly Diagnosed Acute Leukemia Patient's Emotional Functioning During Induction Chemotherapy as Measured by the Brief Symptom Inventory-18 (BSI-18).

Improved Survival using Dual Monoclonal Antibody Therapy with Aggressive Anti-Microbial Prophylaxis In Steroid-Refractory Acute Graft-Versus-Host Disease

Minimizing Therapy for Patients with Acute Promyelocytic Leukemia: Efficacy of Single Cycle of Arsenic-Based Consolidation Therapy.

Active Oral Regimen for Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML): Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults ≥Age 70 Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

Tipifarnib (Zarnestra, R115777) as Maintenance Therapy for Adults in Complete Remission (CR) Following Induction and Consolidation Therapies for Poor-Risk Acute Myelogenous Leukemia (AML): A Phase II Trial.

Tipifarnib (ZARNESTRA TM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only